Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer

This publication has 30 references indexed in Scilit:

• A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies
  EBioMedicine, 2024
• Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
  Annals of Oncology, 2023
• Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
  JAMA Oncology, 2023
• Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab
  JAMA Oncology, 2023
• Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer
  JAMA Oncology, 2023
• Multi-modal profiling of peripheral blood cells across the human lifespan reveals distinct immune cell signatures of aging and longevity
  EBioMedicine, 2023
• Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
  The Lancet Oncology, 2023
• Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer
  Immunity, 2022
• Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
  EBioMedicine, 2022
• Dual role of the tyrosine activation motif of the Ig‐alpha protein during signal transduction via the B cell antigen receptor.
  The EMBO Journal, 1994